Advancing Patient Access to NGS for cancer in APAC

Roche Diagnostics Asia Pacific posted on LinkedIn:

“Did you know that clinical outcomes for cancer in APAC have an estimated mortality-to-incidence ratio (MIR) of 0.52 as compared to 0.32 in the West?

This is why innovative technologies like Next-Generation Sequencing (NGS) are a potential game-changer in cancer care. This latest paper written by Asia Pacific Medical Technology Association (APACMed), explores NGS’s role in personalized treatment, its real-world impact on patient outcomes, and a value assessment framework to improve access.               .

Read about this in the whitepaper here.”

Source: Roche Diagnostics Asia Pacific/LinkedIn